Jay B. Lichter - 15 Jun 2021 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director, 10%+ Owner
Signature
/s/ Tighe Reardon, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
15 Jun 2021
Net transactions value
+$10,699,987
Form type
4
Filing time
16 Jun 2021, 18:05:49 UTC
Previous filing
10 Jun 2021
Next filing
24 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Conversion of derivative security +1,138,665 +593% 1,330,815 15 Jun 2021 See footnote F1, F2
transaction JANX Common Stock Conversion of derivative security +2,382,191 +179% 3,713,006 15 Jun 2021 See footnote F1, F2
transaction JANX Common Stock Conversion of derivative security +674,211 +18% 4,387,217 15 Jun 2021 See footnote F1, F2
transaction JANX Common Stock Conversion of derivative security +2,696,843 2,696,843 15 Jun 2021 See footnote F1, F3
transaction JANX Common Stock Conversion of derivative security +1,153,238 +43% 3,850,081 15 Jun 2021 See footnote F1, F3
transaction JANX Common Stock Purchase $10,699,987 +629,411 +16% $17.00 4,479,492 15 Jun 2021 See footnote F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Series Seed Convertible Preferred Stock Conversion of derivative security -888,888 -100% 0 15 Jun 2021 Common Stock 1,138,665 See footnote F1, F2
transaction JANX Series Seed 2 Convertible Preferred Stock Conversion of derivative security -1,859,634 -100% 0 15 Jun 2021 Common Stock 2,382,191 See footnote F1, F2
transaction JANX Series A Convertible Preferred Stock Conversion of derivative security -526,316 -100% 0 15 Jun 2021 Common Stock 674,211 See footnote F1, F2
transaction JANX Series A Convertible Preferred Stock Conversion of derivative security -2,105,264 -100% 0 15 Jun 2021 Common Stock 2,696,843 See footnote F1, F3
transaction JANX Series B Convertible Preferred Stock Conversion of derivative security -900,264 -100% 0 15 Jun 2021 Common Stock 1,153,238 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
F2 The shares are directly held by Avalon Ventures XI, L.P. (Avalon Ventures). Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Dr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. Dr. Lichter disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any.
F3 The shares are directly held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter shares voting and investment power with respect to the shares held by ABV SPV. Dr. Lichter disclaims beneficial ownership of all shares held by ABV SPV except to the extent of his actual pecuniary interest therein, if any.
F4 The shares were purchased in the Issuer's initial public offering.